Tower Research Capital (TRC)’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Tower Research Capital (TRC)’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-508	Closed	-$10.8K	–	6126
2024 Q1	$10.8K	Sell	508 -2,500	-83%	-$29.9K	﹤0.01%	3641
2023 Q4	$28.9K	Buy	3,008 +2,869	+2,064%	+$13.9K	﹤0.01%	3445
2023 Q3	$361	Buy	+139	New	+$446	﹤0.01%	5590
2022 Q3	–	Sell	-3,259	Closed	-$8K	–	6637
2022 Q2	$8K	Buy	+3,259	New	+$15K	﹤0.01%	4725
2022 Q1	–	Sell	-1,160	Closed	-$5K	–	6725
2021 Q4	$5K	Sell	1,160 -1,494	-56%	-$9.32K	﹤0.01%	5217
2021 Q3	$21K	Sell	2,654 -361	-12%	-$3.04K	﹤0.01%	3684
2021 Q2	$24K	Buy	3,015 +1,457	+94%	+$12.5K	﹤0.01%	3744
2021 Q1	$17K	Buy	+1,558	New	+$18.2K	﹤0.01%	4023

Tower Research Capital (TRC)'s FUSN Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 508 shares — an estimated $10.8K sold.

Tower Research Capital (TRC) first reported a position in FUSN in Q1 2021 and held it in 8 quarters. The position peaked at $28.9K in Q4 2023. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

Tower Research Capital (TRC) reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 508 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $10.8K.
Tower Research Capital (TRC) first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q1 2021 and held it in 8 quarters.
Tower Research Capital (TRC)'s Fusion Pharmaceuticals Inc. Common Shares position peaked at $28.9K in Q4 2023.
0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.